Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.58 |
| ▸ | ACR | P10323 | 1/20 | 0.58 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.58 |
| ▸ | SLC22A2 | O15244 | 6/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 6/20 | 0.56 |
| ▸ | SLC22A3 | O75751 | 6/20 | 0.56 |
| ▸ | PLAU | P00749 | 5/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Guanidino-Benzoic Acid SCHEMBL20488250 | 0.96 | CA12 (0.92) | CA12CA1CA2CA9ADRA2A | |
| SCHEMBL31415103 | 0.84 | CA1 (0.73) | CA12CA1CA2CA9ADRA2A | |
| SCHEMBL6299889 | 0.84 | ADRA2A (0.75) | CA12CA1CA2CA9ADRA2A | |
| Hydrochloric Acid SCHEMBL11226185 | 0.82 | NOS1 (0.73) | CA12CA1CA2CA9ADRA2A | |
| SCHEMBL6931411 | 0.80 | NOS1 (0.80) | CA12CA1CA2CA9ADRA2A | |
| SCHEMBL27566974 | 0.79 | MEN1 (0.70) | CA12CA1CA2CA9ADRA2A | |
| SCHEMBL31398620 | 0.78 | NOS1 (0.68) | CA12CA1CA2CA9ADRA2A | |
| SCHEMBL4881324 | 0.77 | CA1 (0.63) | CA12CA1CA2CA9POLB | |
| SCHEMBL4881332 | 0.77 | CA1 (0.63) | CA12CA1CA2CA9POLB | |
| Terephthalic Acid SCHEMBL27473772 | 0.77 | TSHR (0.80) | CA12CA1CA2CA9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | claimed |
| EP-2560486-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | claimed |
| EP-2663187-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG | SIGNATURE THERAPEUTICS INC (US) | 2016-06-01 | — | — | EP | claimed |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-06-20 | — | — | US | disclosed |
| US-20210251942-A1 | 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME | UNIV COLORADO REGENTS (US) | 2021-08-19 | — | — | US | disclosed |
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| CN-1649555-A | Absorbent article containing a skin care composition | SCA HYGIENE PROD AB (SE) | 2005-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | CA12 4576/4885CA1 3726/4885CA2 2219/4885 |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | TMPRSS2, TMPRSS4, TMPRSS15 | CA12 494/4885CA1 1394/4885CA2 719/4885 |
| US-20210251942-A1 | 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME | TMPRSS2, TMPRSS4, TMPRSS15 | CA12 494/4885CA1 1394/4885CA2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.